Molecular Partners and Orano Med Forge Partnership to Advance Radio-DARPin Therapies

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- In a pioneering move to enhance the field of targeted radiotherapy, Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN and Orano Med have announced a significant co-development agreement. Molecular Partners AG, a trailblazer in the clinical-stage biotech sphere, is well-known for its novel class of bespoke protein therapeutics known as Designed Ankyrin Repeat Proteins (DARPins). These engineered proteins show considerable promise for their ability to target specific disease pathways with high precision and affinity.

The Synergy of DARPin and Radiotherapy

The collaboration between Molecular Partners and Orano Med marks a notable advance in the pursuit of innovative cancer treatments. By integrating the targeting capabilities of DARPins with the localized treatment potential of radiotherapy, the partnership aims to develop Radio-DARPin therapies. These therapies are expected to deliver radioactive isotopes directly to tumor cells, limiting damage to surrounding healthy tissue and potentially enhancing the efficacy and safety profiles of cancer treatments.

Strategic Development and Commercialization

Molecular Partners and Orano Med's co-development agreement delineates a strategic path for advancing the Radio-DARPin therapies. The partnership will leverage both companies' strengths, with Molecular Partners contributing its proprietary DARPin platform and Orano Med offering its expertise in crafting targeted radiotherapeutics. They will jointly carry out research, development, and future commercialization, aiming to create a new paradigm in precision oncology.

biotech, radiotherapy, DARPin